Silo Pharma, Inc.
SILO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.89 | 0.04 | 0.01 | -0.00 |
| FCF Yield | -117.05% | -72.71% | -45.57% | -839.62% |
| EV / EBITDA | 0.14 | -0.25 | 0.95 | -2.29 |
| Quality | ||||
| ROIC | -81.76% | -55.31% | -32.37% | -27.28% |
| Gross Margin | 91.90% | 91.90% | 91.90% | 92.98% |
| Cash Conversion Ratio | 0.87 | 0.87 | 0.89 | -0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.00% | 0.39% | – | 20.66% |
| Free Cash Flow Growth | -18.90% | 7.81% | -53.54% | -96.89% |
| Safety | ||||
| Net Debt / EBITDA | 0.89 | 0.97 | 2.91 | -2.35 |
| Interest Coverage | -925.59 | -791.87 | -1,649.68 | -903.93 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -99,027.35 | -43,983.06 | -22,437.14 | -30,485.01 |